fig7

The impact of rituximab prophylaxis on hepatocellular carcinoma recurrence after living donor liver transplantation

Figure 7. Overall survival (A) and recurrence (B) rates following LT in relation to rituximab administration in patients with HCC as per UCSF critera. HCC: Hepatocellular carcinoma; LT: liver transplantation; UC: UCSF criteria.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/